» Articles » PMID: 30402608

Epidemiology of Cutaneous Adverse Drug Reactions

Overview
Journal Allergol Select
Date 2018 Nov 8
PMID 30402608
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Epidemiologic investigation of cutaneous adverse drug reactions (cADRs) is important in order to evaluate their impact on dermatology and health care in general as well as their burden on affected patients. Few epidemiologic studies have been performed on frequent non-life-threatening cADR, including reactions of both delayed and immediate hypersensitivity, such as maculopapular exanthema (MPE), fixed drug eruption, and urticaria. Concerning rare but life-threatening severe cutaneous adverse reactions, e.g., toxic epidermal necrolysis (TEN), Stevens-Johnson syndrome (SJS), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS), several epidemiologic studies have been performed to date, some of which are still ongoing. Such studies enable the calculation of reliable incidence rates and demographic data, and also allow researchers to perform risk estimation for drugs. The spectrum of drugs causing cADR differs substantially when separating the various clinical conditions. Whereas antibiotics are by far the most frequent inducers of milder cADRs, like MPE, they have a much lower risk of inducing SJS/TEN, for which "high-risk" drugs are anti-infective sulfonamides, allopurinol, certain anti-epileptic drugs, nevirapine, and non-steroidal anti-inflammatory drugs (NSAIDs) of the oxicam-type. In contrast, AGEP is predominantly caused by the antibiotics pristinamycin and aminopenicillins, followed by quinolones, (hydroxy-)chloroquine, and sulfonamides. DRESS can be induced by a number of drugs known to cause SJS/TEN, such as certain antiepileptics and allopurinol, but also other medications (e.g., minocyclin).

Citing Articles

Immune checkpoint inhibitor-induced severe epidermal necrolysis mediated by macrophage-derived CXCL10 and abated by TNF blockade.

Chen C, Hung S, Chang J, Yang C, Ma D, Teng Y Nat Commun. 2024; 15(1):10733.

PMID: 39737932 PMC: 11685864. DOI: 10.1038/s41467-024-54180-7.


Exploring recent advances in drugs severe cutaneous adverse reactions immunopathology.

Cadot R, Gery P, Lenief V, Nicolas J, Vocanson M, Tauber M Allergy. 2024; 80(1):47-62.

PMID: 39295209 PMC: 11724259. DOI: 10.1111/all.16316.


A Rare Pediatric Case of Allopurinol-Induced Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS) Successfully Treated With Intravenous Immunoglobulins.

Rotulo G, Campanello C, Battaglini M, Bassi M, Pastorino C, Angeletti A J Pediatr Pharmacol Ther. 2024; 29(2):195-199.

PMID: 38596415 PMC: 11001218. DOI: 10.5863/1551-6776-29.2.195.


Causes and Management of Cutaneous Adverse Drug Reactions: A Comprehensive Review.

Sutaria A, Rawlani S, Sutaria A Cureus. 2024; 16(3):e55318.

PMID: 38562325 PMC: 10982164. DOI: 10.7759/cureus.55318.


Evaluation of severe adverse cutaneous drug reactions in patients admitted to tertiary care center: A cross-sectional study.

Moshayedi M, Asilian A, Mokhtari F Health Sci Rep. 2024; 7(3):e1969.

PMID: 38486684 PMC: 10937814. DOI: 10.1002/hsr2.1969.


References
1.
Sassolas B, Haddad C, Mockenhaupt M, Dunant A, Liss Y, Bork K . ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson Syndrome and toxic epidermal necrolysis: comparison with case-control analysis. Clin Pharmacol Ther. 2010; 88(1):60-8. DOI: 10.1038/clpt.2009.252. View

2.
Kelly J, Auquier A, Rzany B, Naldi L, Bastuji-Garin S, Correia O . An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. J Clin Epidemiol. 1995; 48(9):1099-108. DOI: 10.1016/0895-4356(95)00004-n. View

3.
Fagot J, Mockenhaupt M, Bouwes-Bavinck J, Naldi L, Viboud C, Roujeau J . Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS. 2001; 15(14):1843-8. DOI: 10.1097/00002030-200109280-00014. View

4.
Hunziker T, Kunzi U, Braunschweig S, Zehnder D, Hoigne R . Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy. 1997; 52(4):388-93. DOI: 10.1111/j.1398-9995.1997.tb01017.x. View

5.
Kardaun S, Sekula P, Valeyrie-Allanore L, Liss Y, Chu C, Creamer D . Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013; 169(5):1071-80. DOI: 10.1111/bjd.12501. View